| 1 |
NCT03350815 |
Not yet recruiting |
Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis |
|
- Drug: 150 mg open-label secukinumab
- Drug: 150 mg double-blinded secukinumab
- Drug: 300 mg double-blinded secukinumab
|
Interventional |
Phase 4 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- The proportion of participants who achieve inactive disease based on the Ankylosing Spondylitis Disease Activity Score (ASDAS) measure
- The proportion of participants who achieve a clinically important improvement on the Ankylosing Spondylitis Disease Activity Score (ASDAS) scale
- Change over time in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
- (and 7 more...)
|
270 |
All |
18 Years and older (Adult, Senior) |
NCT03350815 |
CAIN457FUS06 |
ASLeap |
March 5, 2018 |
April 1, 2020 |
April 1, 2020 |
November 22, 2017 |
February 13, 2018 |
|
|
| 2 |
NCT03457285 |
Not yet recruiting |
Investigating the Use of Salaso to Improve Physiotherapy Management of Ankylosing Spondylitis (AS). |
|
|
Interventional |
Not Applicable |
- St. James's Hospital, Ireland
- Salaso Health Solutions Limited
- Novartis
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Bath Ankylosing Spondylitis Metrology Index
- Bath Ankylosing Spondylitis Disease Activity Index
- Bath Ankylosing Spondylitis Functional Index
- (and 2 more...)
|
20 |
All |
18 Years and older (Adult, Senior) |
NCT03457285 |
SJH AS Salaso Study |
|
April 9, 2018 |
October 9, 2018 |
October 31, 2018 |
March 7, 2018 |
March 7, 2018 |
|
- Physiotherapy Department, Saint James's Hospital
Dublin, Ireland
|
| 3 |
NCT03140657 |
Recruiting |
The Effects of Nanocurcumin on Serum miRNA and Th17 Cells Development Factors in Ankylosing Spondylitis Patients |
|
- Drug: Nanocurcumin
- Drug: Placebo
|
Interventional |
Phase 2 |
- Tabriz University of Medical Sciences
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Assessments of Ankylosing Spondylitis (ASAS) 20 Response
- Serum mir-326 expression
- Serum IL-17 levels
- (and 3 more...)
|
25 |
All |
18 Years to 65 Years (Adult) |
NCT03140657 |
TabrizUMS-Rheumatology-003 |
|
April 29, 2017 |
May 28, 2018 |
June 7, 2018 |
May 4, 2017 |
January 30, 2018 |
|
- Connective Tissue Diseases Research Center
Tabriz, Iran, Islamic Republic of
|
| 4 |
NCT02333383 |
Completed |
Observe the Frequency of Extra-Axial Symptoms in Korean Ankylosing Spondylitis (AS) Patients |
|
|
Observational |
|
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Frequency of Extra-Axial Manifestations (EAMs) of interest in Korean AS patients
- Percentage of subjects with 50% improvement of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score
- Change in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)
- (and 4 more...)
|
201 |
All |
19 Years to 100 Years (Adult, Senior) |
NCT02333383 |
P15-238 |
AS PMOS |
December 31, 2014 |
August 8, 2017 |
August 8, 2017 |
January 7, 2015 |
August 15, 2017 |
|
- Hallym University Sacred Heart Hospital /ID# 135329
Anyang-si, Korea, Republic of - Dong-A University Hospital /ID# 135232
Busan, Korea, Republic of - Daegu Catholic University Medical Center /ID# 135349
Daegu, Korea, Republic of - (and 10 more...)
|
| 5 |
NCT02201043 |
Completed |
Phase II Clinical Study of Thalidomide in the Treatment of Ankylosing Spondylitis |
|
- Drug: Thalidomide 150mg
- Drug: Thalidomide 100mg
- Drug: Placebo
|
Interventional |
Phase 2 |
- Shanghai Pharmaceuticals Holding Co., Ltd
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of Subjects Achieving Assessment in Ankylosing Spondylitis 20 (ASAS 20)
- Change of ASDAS score
- Mean change from baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
- (and 11 more...)
|
197 |
All |
18 Years to 65 Years (Adult) |
NCT02201043 |
SLDA-201 |
|
February 2013 |
February 2015 |
February 2015 |
July 25, 2014 |
November 20, 2015 |
|
- The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, China - The General Hospital of People's Liberation Army
BeiJing, Beijing, China - Zhongshan Hospital Fudan University
Shanghai, Shanghai, China - (and 6 more...)
|
| 6 |
NCT01079182 |
Completed
Has Results |
Basic Documentation of Adalimumab (Humira) in Patients With Ankylosing Spondylitis (AS) |
|
|
Observational |
|
- AbbVie (prior sponsor, Abbott)
- AbbVie
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Mean Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score
- Mean Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) Score
- Number of Participants With Drug-Related Adverse Events (AEs)
- (and 21 more...)
|
4681 |
All |
18 Years and older (Adult, Senior) |
NCT01079182 |
P10-147 |
|
January 2006 |
May 2014 |
May 2014 |
March 3, 2010 |
July 9, 2015 |
June 1, 2015 |
|
| 7 |
NCT00667355 |
Completed
Has Results |
A Study of Adalimumab in Japanese Subjects With Active Ankylosing Spondylitis |
|
|
Interventional |
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Subjects Achieving Assessment in Ankylosing Spondylitis 20 (ASAS 20) at Week 12
- Number of Subjects Achieving ASAS 20
- Number of Subjects Achieving ASAS 50
- (and 16 more...)
|
41 |
All |
15 Years and older (Child, Adult, Senior) |
NCT00667355 |
M10-239 |
|
February 2008 |
May 2009 |
January 2011 |
April 28, 2008 |
January 26, 2012 |
August 11, 2010 |
- Site Reference # / Investigator 46791
Aichi, Japan - Site Reference # / Investigator 46789
Fukui, Japan - Site Reference # / Investigator 46798
Fukuoka, Japan - (and 16 more...)
|
| 8 |
NCT01754727 |
Completed
Has Results |
Impact of Adalimumab (Humira®) Therapy on Selected Health Care Resource Utilization and Sick Leave in Patients With Ankylosing Spondylitis in Clinical Practice |
|
|
Observational |
|
- AbbVie (prior sponsor, Abbott)
- AbbVie
|
Industry |
- Time Perspective: Prospective
|
- Percentage of Participants Achieving Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 at Month 12
- Percentage of Participants Achieving BASDAI 50
- Percentage of Participants Achieving At Least 2.0 Score Decrease in Ankylosing Spondylitis Disease Activity (ASDAS) Score From Baseline
- (and 8 more...)
|
452 |
All |
18 Years and older (Adult, Senior) |
NCT01754727 |
P13-682 |
IDEA |
December 2012 |
October 2015 |
October 2015 |
December 21, 2012 |
March 6, 2017 |
March 6, 2017 |
|
| 9 |
NCT03502616 |
Not yet recruiting
New |
Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS) |
|
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Assessment in Ankylosing Spondylitis (ASAS) 20 response
- Assessment in Ankylosing Spondylitis (ASAS) 40 response
- Assessment in Ankylosing Spondylitis (ASAS) 5/6 response
- (and 20 more...)
|
240 |
All |
18 Years and older (Adult, Senior) |
NCT03502616 |
A3921120
AS |
|
June 26, 2018 |
August 2, 2020 |
August 2, 2020 |
April 18, 2018 |
April 18, 2018 |
|
|
| 10 |
NCT01286545 |
Unknown † |
European Ankylosing Spondylitis Infliximab Cohort (EASIC) Follow up Registration Study |
|
|
Observational |
|
- Rheumazentrum Ruhrgebiet
- Centocor Ortho Biotech Services, L.L.C.
|
Other / Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
|
100 |
All |
18 Years to 95 Years (Adult, Senior) |
NCT01286545 |
EASIC 30505 registry |
EASIC registry |
February 2011 |
July 2013 |
October 2013 |
January 31, 2011 |
January 31, 2011 |
|
- Erasme University Hospital
Brussels, Belgium - Universitair Ziekenhuis, Afdeling Rheumatologie
Gent, Belgium - University Hospital Leuven
Leuven, Belgium - (and 16 more...)
|
| 11 |
NCT03259074 |
Not yet recruiting |
Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar) |
|
- Biological: Secukinumab
- Biological: GP2017 (adalimumab biosimilar)
|
Interventional |
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- No radiographic progression as measured by modified Stoke Ankylosing Spondylitis Spine Score (mSASSS)
- Change from baseline in modified Stoke Ankylosing Spondylitis Spine Score (mSASSS)
- No new syndesmophytes as measured by mSASSS
- (and 6 more...)
|
837 |
All |
18 Years and older (Adult, Senior) |
NCT03259074 |
CAIN457K2340 |
SURPASS |
November 14, 2017 |
October 28, 2021 |
November 11, 2021 |
August 23, 2017 |
November 17, 2017 |
|
|
| 12 |
NCT00247962 |
Completed
Has Results |
Study Evaluating Etanercept and Sulphasalazine in Ankylosing Spondylitis |
|
- Drug: etanercept
- Drug: sulphasalazine (SSZ)
|
Interventional |
Phase 4 |
- Wyeth is now a wholly owned subsidiary of Pfizer
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Number of Patients Achieving Assessment in Ankylosing Spondylitis (ASAS 20)
- Ankylosing Spondylitis Quality of Life (ASQoL) Total Score Change From Baseline
|
566 |
All |
18 Years and older (Adult, Senior) |
NCT00247962 |
0881A3-402 |
|
December 2005 |
February 2008 |
February 2008 |
November 2, 2005 |
November 8, 2012 |
November 8, 2012 |
- Heidelberg West, Victoria, Australia
- Shenton Park, Western Australia, Australia
- Innsbruck, Austria
- (and 80 more...)
|
| 13 |
NCT01895764 |
Completed |
Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS) |
|
- Drug: Adalimumab
- Drug: Methotrexate
|
Interventional |
Phase 4 |
- University Hospital, Tours
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- presence or absence of antibodies against adalimumab
- Change from baseline of the Ankylosing Spondylitis Disease Activity Score (ASDAS)
- Change from baseline of T and B cells concentrations.
- Change from baseline of "APRIL" and "TNF alpha" concentrations
|
110 |
All |
18 Years and older (Adult, Senior) |
NCT01895764 |
PHRI12-ED-COMARIS
2012-004939-23
A130042-32
2012-R41 |
COMARIS |
March 2013 |
April 2015 |
April 2015 |
July 10, 2013 |
September 29, 2015 |
|
- Rhumatologie, CH de BLOIS
Blois, France - Rhumatologie, CHRU de BREST
Brest, France - Rhumatologie, CHD LA ROCHE SUR YON
La Roche Sur Yon, France - (and 8 more...)
|
| 14 |
NCT01329380 |
Completed |
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation) |
|
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Bath ankylosing spondylitis Disease Activity Index
- Number of patients with adverse events
- Effectiveness evaluation by the investigator
|
401 |
All |
16 Years to 99 Years (Child, Adult, Senior) |
NCT01329380 |
P12-764 |
|
November 29, 2010 |
December 31, 2017 |
December 31, 2017 |
April 5, 2011 |
January 26, 2018 |
|
- Nagoya City University Hospital
Nagoya-shi, Aichi, Japan - Kurume University Hospital
Kurume-shi, Fukuoka, Japan - Gunma University Hospital
Maebashi-shi, Gunma, Japan - (and 191 more...)
|
| 15 |
NCT00873730 |
Completed
Has Results |
Study Evaluating Etanercept in Subjects With Ankylosing Spondylitis in Spain |
|
- Drug: etanercept
- Drug: etanercept/placebo
|
Interventional |
Phase 4 |
- Wyeth is now a wholly owned subsidiary of Pfizer
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- Number of Patients Achieving Assessment in Ankylosing Spondylitis (ASAS) 20.
- Number of Patients Achieving Assessment in Ankylosing Spondylitis (ASAS) 40.
- Number of Patients Achieving Assessment in Ankylosing Spondylitis (ASAS) 50.
- (and 13 more...)
|
108 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT00873730 |
0881A3-406 |
Loadet |
December 2006 |
June 2008 |
June 2008 |
April 2, 2009 |
April 28, 2010 |
August 13, 2009 |
|
| 16 |
NCT01474876 |
Completed
Has Results |
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis |
- Ankylosing Spondylitis
- Psoriatic Arthritis
|
|
Observational |
|
- AbbVie (prior sponsor, Abbott)
- AbbVie
|
Industry |
- Time Perspective: Prospective
|
- Percentage of Participants With a 50% or More Decrease in Bath Ankylosing Spondylitis Daily Activity Index (BASDAI) Score at 12 Months Relative to Baseline
- Percentage of Participants With a Disease Activity Score 28 (DAS28) Decrease ≥1.2 at 12 Months Relative to Baseline
- Percentage of Participants With Active Axial Symptoms in Remission
- (and 17 more...)
|
566 |
All |
18 Years and older (Adult, Senior) |
NCT01474876 |
P12-768 |
|
November 2011 |
May 2014 |
May 2014 |
November 18, 2011 |
July 8, 2015 |
July 8, 2015 |
|
| 17 |
NCT03117270 |
Active, not recruiting |
A Study to Assess Efficacy and Safety of Filgotinib in Ankylosing Spondylitis |
|
- Drug: filgotinib
- Drug: Placebo Oral Tablet
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Ankylosing Spondylitis disease activity score (ASDAS) in filgotinib treated subjects as compared to placebo
- Assessment of SpondyloArthritis international Society (ASAS) in filgotinib treated subjects as compared to placebo
- Assessment by a trained joint assessor of 44 joints for tenderness (counting the number or tender joints - TJC) and swelling (counting the number of swollen joints - SJC) in filgotinib treated subjects as compared to placebo
- (and 14 more...)
|
116 |
All |
18 Years and older (Adult, Senior) |
NCT03117270 |
GLPG0634-CL-223 |
TORTUGA |
March 7, 2017 |
May 2018 |
May 2018 |
April 17, 2017 |
March 12, 2018 |
|
- ULB Hopital Erasme, Service de Rheumatology
Brussels, Belgium - Eurohospital
Plovdiv, Bulgaria - UMHAT Kaspela EOOD
Plovdiv, Bulgaria - (and 27 more...)
|
| 18 |
NCT03215277 |
Recruiting |
Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis. |
|
- Drug: Bimekizumab
- Drug: Certolizumab Pegol
- Other: Placebo
|
Interventional |
Phase 2 |
- UCB Biopharma S.P.R.L.
- UCB Pharma
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 12
- Incidence of Adverse Events (AE) during the study conduct
- Incidence of Serious Adverse Events (SAEs) during the study conduct
- (and 5 more...)
|
60 |
All |
18 Years and older (Adult, Senior) |
NCT03215277 |
AS0013
2017-000957-37 |
|
October 4, 2017 |
September 2018 |
September 2019 |
July 12, 2017 |
April 12, 2018 |
|
- As0013 908
Ormond Beach, Florida, United States - As0013 901
Tampa, Florida, United States - As0013 903
Lincoln, Nebraska, United States - (and 30 more...)
|
| 19 |
NCT00809159 |
Completed
Has Results |
Double Blind, Placebo Controlled Study to Assess Efficacy of AIN457 in Moderate to Severe Ankylosing Spondylitis |
|
- Biological: AIN457
- Drug: Placebo
|
Interventional |
Phase 2 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
|
- Percentage of Participants Who Achieved ASAS20 Response
- Change in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score From Baseline to 6 Weeks After First Infusion in Part 2
- Number of Participants Who Achieved ASAS20, ASAS40, and ASAS 5/6 Over Time in Part 1
- (and 20 more...)
|
60 |
All |
18 Years to 65 Years (Adult) |
NCT00809159 |
CAIN457A2209
2008-002631-33 |
|
March 2009 |
May 2011 |
May 2011 |
December 17, 2008 |
December 9, 2015 |
September 18, 2015 |
- Novartis Investigative Site
Paradise Valley, Arizona, United States - Novartis Investigative Site
Springfield, Illinois, United States - Novartis Investigative Site
Springfield, Illinois, United States - (and 17 more...)
|
| 20 |
NCT01248793 |
Completed
Has Results |
Study of the Safety and Efficacy of Golimumab in Chinese Patients With Ankylosing Spondylitis |
|
- Drug: Placebo
- Drug: Golimumab
- Drug: Golimumab (placebo group)
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Assessment of Ankylosing Spondylitis Response (ASAS 20) at Week 14
- Assessment of Ankylosing Spondylitis Response (ASAS 20) at Week 24
- Change From Baseline in the Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 14
- Change From Baseline in the Bath Ankylosing Spondylitis Metrology Index (BASMI) at Week 14
|
213 |
All |
18 Years and older (Adult, Senior) |
NCT01248793 |
CR015916
C0524T29 |
|
October 2010 |
May 2011 |
March 2012 |
November 25, 2010 |
March 20, 2013 |
June 28, 2012 |
- Beijing, China
- Chengdu, China
- Guangzhou, China
- (and 4 more...)
|
| 21 |
NCT02525042 |
Completed |
Genetic Susceptibility to Ankylosing Spondylitis (AS) by Functional Genomics Approach |
|
|
Observational |
|
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Observational Model: Family-Based
- Time Perspective: Retrospective
|
- Comparison of the transcriptome of dendritic cells derived from circulating monocytes between cases and controls
- Assessment of manifestations of Ankylosing Spondylitis (AS) according an Updating Questionnaire.
|
97 |
All |
18 Years and older (Adult, Senior) |
NCT02525042 |
NI09031 |
GENOSPA |
August 2011 |
January 2014 |
|
August 17, 2015 |
August 17, 2015 |
|
- Ambroise Paré Hospital
Boulogne-Billancourt, Hauts-De-Seine, France
|
| 22 |
NCT01289743 |
Unknown † |
Etanercept (Enbrel) in Ankylosing Spondylitis |
|
|
Interventional |
Phase 2 |
- Charite University, Berlin, Germany
- Rheumazentrum Ruhrgebiet
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)50 response
- Sustained response
- Safety outcome
- (and 2 more...)
|
24 |
All |
18 Years to 65 Years (Adult) |
NCT01289743 |
Enbrel _AS-2
202-04 |
Enbrel_AS-2 |
February 2002 |
September 2003 |
May 2012 |
February 4, 2011 |
February 4, 2011 |
|
- Charite Campus Benjamin Franklin, Rheumatology
Berlin, Germany - Rheumazentrum Ruhrgebiet
Herne, Germany
|
| 23 |
NCT01077843 |
Completed |
Post-authorization Safety Study of Etoricoxib and Other Anti-inflammatory Therapies in European Patients With Ankylosing Spondylitis (MK-0663-163) |
|
- Drug: Etoricoxib
- Drug: Other Cox-2 inhibitors
- Drug: Other Non-selective NSAIDs
- Other: No anti-inflammatory treatment
|
Observational |
|
- Merck Sharp & Dohme Corp.
|
Industry |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Incidence rate of gastrointestinal ulcer, perforation or bleeding
- Incidence rate of fatal or non-fatal acute myocardial infarction or unstable angina pectoris
- Incidence rate of fatal or non-fatal ischemic stroke, or transient ischemic attack
- (and 6 more...)
|
27381 |
All |
Child, Adult, Senior |
NCT01077843 |
0663-163 |
|
August 17, 2009 |
July 1, 2015 |
July 1, 2015 |
March 1, 2010 |
June 7, 2017 |
|
|
| 24 |
NCT03355573 |
Enrolling by invitation |
A Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing Spondylitis |
|
|
Interventional |
Phase 2 |
- UCB Biopharma S.P.R.L.
- UCB Pharma
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of Adverse Event (AE) during the study
- Incidence of Serious Adverse Event (SAE) during the study
- Subjects who withdrew due to an Adverse Event (AE) during the study
- (and 4 more...)
|
285 |
All |
18 Years and older (Adult, Senior) |
NCT03355573 |
AS0009
2017-001002-15 |
|
November 28, 2017 |
December 2022 |
December 2022 |
November 28, 2017 |
April 12, 2018 |
|
- As0009 001
Duncansville, Pennsylvania, United States - As0009 006
Dallas, Texas, United States - As0009 156
Dobrich, Bulgaria - (and 27 more...)
|
| 25 |
NCT02456363 |
Recruiting |
Anti-Tumor Necrosis Factor Therapy In Patients With Ankylosing Spondylitis |
|
- Biological: TNF alpha
- Drug: NSAIDs and sulfasalazine
|
Interventional |
Phase 2 |
- Chung Shan Medical University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- mSASSS (Modified Stoke Ankylosing Spondylitis Spinal Score)
|
300 |
All |
18 Years and older (Adult, Senior) |
NCT02456363 |
CS09128 |
|
November 2009 |
October 2019 |
December 2019 |
May 28, 2015 |
May 28, 2015 |
|
- Chung Shan Medical University Hospital
Taichung, Taiwan
|
| 26 |
NCT02284646 |
Recruiting |
Physical Training Program in Ankylosing Spondylitis |
|
- Other: Personalized physical training program
|
Interventional |
Not Applicable |
- University Hospital, Toulouse
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of patients reaching an ASAS 20 response
|
56 |
All |
18 Years to 60 Years (Adult) |
NCT02284646 |
13 7027 08 |
PEPS |
November 2014 |
October 2017 |
November 2017 |
November 6, 2014 |
February 23, 2017 |
|
- University Hospital
Toulouse, France
|
| 27 |
NCT00420238 |
Completed
Has Results |
Study Evaluating Etanercept for the Treatment of Active, Severe, and Advanced Axial Ankylosing Spondylitis |
|
- Drug: Etanercept (Enbrel)
- Other: Placebo
|
Interventional |
Phase 4 |
- Wyeth is now a wholly owned subsidiary of Pfizer
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Normalized Net Incremental Area Under the Curve (AUC) for the Bath Ankylosing Spondylitis Disease Activities Index (BASDAI) Between Randomization and Week 12
- Percent of Subjects Achieving Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 Response
- Percent of Subjects Achieving Assessment Ankylosing Spondylitis (ASAS) 20 at Weeks 2, 4, 8, 12
- (and 62 more...)
|
82 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT00420238 |
0881A3-403 |
|
January 2007 |
February 2009 |
May 2009 |
January 11, 2007 |
June 29, 2010 |
June 15, 2010 |
- Amiens, France
- Arles, France
- Avignon, France
- (and 18 more...)
|
| 28 |
NCT02963506 |
Active, not recruiting |
A Multicenter Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis |
|
- Other: Placebo
- Drug: Bimekizumab
|
Interventional |
Phase 2 |
- UCB Biopharma S.P.R.L.
- UCB Pharma
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Subjects with Axial Spondyloarthritis International Society 40 % response criteria (ASAS40) at Week 12
- Change from Baseline in Ankylosing Spondylitis Disease Activity Score - C-Reactive Protein (ASDAS [CRP]) at Week 12
- Subjects with Axial Spondyloarthritis International Society 20 % response criteria (ASAS20) at Week 12
- (and 6 more...)
|
303 |
All |
18 Years and older (Adult, Senior) |
NCT02963506 |
AS0008
2016-001102-42 |
|
October 2016 |
October 2017 |
October 2018 |
November 15, 2016 |
March 29, 2018 |
|
- As0008 019
Anniston, Alabama, United States - As0008 007
San Diego, California, United States - As0008 009
Upland, California, United States - (and 71 more...)
|
| 29 |
NCT02758782 |
Recruiting |
NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of Structural Damage in Ankylosing Spondylitis |
|
- Biological: Golimumab
- Drug: Celecoxib
|
Interventional |
Phase 4 |
- Charite University, Berlin, Germany
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Absolute progression of the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) over two years of therapy (weeks 12-108) in the Phase II (core phase) of the trial
- New syndesmophyte formation or progression of existing syndesmophytes
- Improvement of disease activity (BASDAI)
- (and 7 more...)
|
170 |
All |
18 Years and older (Adult, Senior) |
NCT02758782 |
CONSUL2016 |
CONSUL |
September 2016 |
January 2020 |
January 2020 |
May 2, 2016 |
August 21, 2017 |
|
- Rheumapraxis Kupka
Altenburg, Germany - Rheumapraxis Bayreuth Dr. Ochs
Bayreuth, Germany - Charite Universitaetsmedizin - Dpt. Rheumatology at Campus Charite Mitte
Berlin, Germany - (and 18 more...)
|
| 30 |
NCT00195819 |
Completed
Has Results |
Safety and Efficacy of Adalimumab in Patients With Active Ankylosing Spondylitis |
|
- Biological: adalimumab (D2E7)
- Biological: placebo
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Number of Subjects With a Reduction in Signs and Symptoms as Measured by Assessments of Ankylosing Spondylitis (ASAS) 20 Response at Week 12
- Mean Change in the Modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) Compared Against a Historical Control Group (Outcomes in Ankylosing Spondylitis International Study [OASIS]) Using the ANCOVA Model Adjusting for Baseline mSASSS Score
- Number of Subjects With a Reduction of Signs and Symptoms as Measured in Assessments of Ankylosing Spondylitis (ASAS) 20 - Through Week 260 of Adalimumab Exposure
- (and 41 more...)
|
82 |
All |
18 Years and older (Adult, Senior) |
NCT00195819 |
M03-606 |
|
December 2003 |
October 2004 |
June 2009 |
September 20, 2005 |
June 28, 2011 |
April 28, 2010 |
- Site Ref # / Investigator 74
Calgary, Alberta, Canada - Site Ref # / Investigator 70
Edmonton, Alberta, Canada - Site Ref # / Investigator 79
Vancouver, British Columbia, Canada - (and 6 more...)
|
| 31 |
NCT01856569 |
Completed
Has Results |
Assial - Anti Tnf Treatment in Ankylosing Spondylitis: an Observational Cohort Study in Italy |
|
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Other
|
- Percentage of Participants With Unchanged First Line Anti-TNF Treatment Up to Month 18
- Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Total Score at Month 18
- Percentage of Participants With Unchanged First Line Anti-TNF Treatment In State of Low Disease Activity
- (and 3 more...)
|
152 |
All |
18 Years and older (Adult, Senior) |
NCT01856569 |
B1801362 |
ASSIAL |
July 2013 |
October 2015 |
November 2015 |
May 17, 2013 |
March 9, 2017 |
March 9, 2017 |
- Unita Operativa Semplice di Reumatologia
Catania, CT, Italy - U.O.S. Reumatologia - Azienda Ospedaliera Universitaria Policlinico Sant'Orsola-Malpighi
Bologna, Italy - Piazzale Spedali Civili
Brescia, Italy - (and 15 more...)
|
| 32 |
NCT02528201 |
Completed |
A Study Of Celecoxib Versus Diclofenac In Patients With Ankylosing Spondylitis |
|
- Drug: Celecoxib 200 milligrams
- Drug: Celecoxib 400 milligrams
- Drug: diclofenac 50 milligrams
|
Interventional |
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change in baseline of Patient Global Assessment of Pain Intensity (VAS) at week 12
- Participants Global Assessment of Pain Intensity (VAS)
- Bath Ankylosing Spondylitis Functional Index (BASFI)
- (and 4 more...)
|
330 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT02528201 |
COXA-0508-247
A3191099 |
|
September 2002 |
November 2004 |
November 2004 |
August 19, 2015 |
August 19, 2015 |
|
- Bekkestua legesenter
Bekkestua, Norway - Dr. Johannessen Kontor
Bergen, Norway - Dr.Wiigs kontor
Bergen, Norway - (and 24 more...)
|
| 33 |
NCT01351311 |
Completed |
Resistance Training Exercise Using the Swiss Ball in Ankylosing Spondylitis |
|
- Other: Exercise
- Other: Drug treatment
|
Interventional |
Not Applicable |
- Federal University of São Paulo
- Fundação de Amparo à Pesquisa do Estado de São Paulo
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Bath Ankylosing Spondylitis Functional Index (BASFI)
- LIKERT SCALE
- 1 REPETITION MAXIMUM TEST
- (and 8 more...)
|
60 |
All |
18 Years to 60 Years (Adult) |
NCT01351311 |
FDAAAMC |
|
March 2011 |
November 2012 |
November 2012 |
May 10, 2011 |
November 30, 2012 |
|
- Marcelo Cardoso de Souza
Sao Paulo, Brazil
|
| 34 |
NCT02186873 |
Completed
Has Results |
A Study of Golimumab in Participants With Active Ankylosing Spondylitis |
|
- Drug: Placebo
- Drug: Golimumab
|
Interventional |
Phase 3 |
- Janssen Research & Development, LLC
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Percentage of Participants Who Achieved at Least 20 Percent Improvement From Baseline in the Assessment of SpondyloArthritis International Society (ASAS 20) at Week 16
- Percentage of Participants Who Achieved at Least 40 Percent Improvement From Baseline in the Assessment of SpondyloArthritis International Society (ASAS 40) at Week 16
- Percentage of Participants Who Achieved at Least 50 Percent Improvement From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 16
- (and 6 more...)
|
208 |
All |
18 Years and older (Adult, Senior) |
NCT02186873 |
CR103795
CNTO148AKS3001
2014-000241-74 |
|
September 3, 2014 |
December 15, 2015 |
October 11, 2016 |
July 10, 2014 |
December 22, 2017 |
November 13, 2017 |
- Glendale, Arizona, United States
- Mesa, Arizona, United States
- La Palma, California, United States
- (and 44 more...)
|
| 35 |
NCT01709656 |
Completed |
A Molecule Basic Study of Early Warning for New Pathogenic Risk of Ankylosing Spondylitis |
|
- Biological: MSC
- Drug: "celecoxib", "Celebrex®"
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
|
- the proportion of patients which disease activity reaches ASAS(assessment in ankylosing Spondylitis)20 remission criteria
- BASDAI score comparing to baseline
- BASFI score comparing to baseline
|
120 |
All |
16 Years to 65 Years (Child, Adult) |
NCT01709656 |
[2012]2-31 |
|
March 2012 |
December 2014 |
December 2014 |
October 18, 2012 |
February 11, 2015 |
|
- Department of Rheumatology, the Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
|
| 36 |
NCT01690273 |
Completed
Has Results |
Exercise Therapy Program in Ankylosing Spondylitis Patients |
|
- Other: mobility exercise
- Other: mobility and elastic resistance exercise
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- FUNCTIONAL INDEX
- Mobility Index
- Disease Activity Index
- (and 12 more...)
|
55 |
All |
Child, Adult, Senior |
NCT01690273 |
8206212 |
|
July 2012 |
June 2013 |
November 2014 |
September 21, 2012 |
October 20, 2016 |
October 20, 2016 |
- University of Sao Paulo
Sao Paulo, Brazil
|
| 37 |
NCT03447704 |
Recruiting |
International Multicenter Comparative Randomized Placebo-controlled Clinical Study of Efficacy and Safety of BCD-085 in Patients With Ankylosing Spondylitis |
|
- Drug: BCD-085
- Other: placebo
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- ASAS40 rate at Week 16
- ASAS20 rate
- Change from baseline in BASDAI
- (and 3 more...)
|
228 |
All |
18 Years to 65 Years (Adult) |
NCT03447704 |
BCD-085-5 |
|
February 8, 2018 |
January 2019 |
February 2020 |
February 27, 2018 |
March 7, 2018 |
|
- Non-governmental Healthcare Institution "Railway Clinical hospital on the Chelyabinsk Station of JSC Russian Railways"
Chelyabinsk, Russian Federation - Chelyabinsk Regional Clinical hospital
Chelyabinsk, Russian Federation - Kazan State Medical University
Kazan, Russian Federation - (and 4 more...)
|
| 38 |
NCT03178487 |
Recruiting |
A Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects With Active Ankylosing Spondylitis |
|
- Drug: Upadacitinib
- Drug: Upadacitinib Placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Other
|
- Proportion of participants with Assessment of SpondyloArthritis international Society (ASAS) 40 response
- Change from Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)
- Proportion of participants with ASAS partial remission (PR)
- (and 10 more...)
|
170 |
All |
18 Years to 99 Years (Adult, Senior) |
NCT03178487 |
M16-098
2017-000431-14 |
SELECT Axis 1 |
October 24, 2017 |
December 7, 2018 |
September 27, 2020 |
June 7, 2017 |
April 3, 2018 |
|
- AZ Arthritis and Rheum Researc
Phoenix, Arizona, United States - Arizona Arthritis & Rheumatolo
Phoenix, Arizona, United States - David S. Hallegua MD
Beverly Hills, California, United States - (and 101 more...)
|
| 39 |
NCT01387802 |
Active, not recruiting |
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis |
|
|
Observational |
|
- AbbVie (prior sponsor, Abbott)
- JSS Medical Research Inc.
- Cato Research
- AbbVie
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Occurrence, flare-up or exacerbation of Extra Articular Manifestations in Uveitis
- Occurrence, flare-up or exacerbation of Extra Articular Manifestations in Psoriasis
- Occurrence, flare-up or exacerbation of Extra Articular Manifestations in Inflammatory Bowel Disease
- (and 4 more...)
|
719 |
All |
18 Years to 99 Years (Adult, Senior) |
NCT01387802 |
P12-672 |
Complete-AS |
June 29, 2011 |
November 30, 2019 |
November 30, 2019 |
July 6, 2011 |
February 9, 2018 |
|
- Rheumatology Clinic
Calgary, Alberta, Canada - Associate Clinic
Calgary, Alberta, Canada - How, Burnaby, CA
Burnaby, British Columbia, Canada - (and 62 more...)
|
| 40 |
NCT00900796 |
Completed
Has Results |
Study Evaluating Predictors of Response in Patients With Ankylosing Spondylitis |
|
- Other: Treatment switching
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Percentage of Participants With a Clinical Response
- Percentage of Participants With High Probability of Response and no Response Who Received Second Anti-TNF Treatment
- Percentage of Participants With Low Probability of Response and no Response Who Received Second Anti-TNF Treatment
- (and 4 more...)
|
132 |
All |
18 Years and older (Adult, Senior) |
NCT00900796 |
0881A3-4452
B1801100 |
PRETEA |
March 2009 |
May 2011 |
May 2011 |
May 13, 2009 |
June 19, 2012 |
June 19, 2012 |
- Pfizer Investigational Site
Madrid, Spain
|
| 41 |
NCT01114880 |
Completed
Has Results |
Efficacy and Safety of Adalimumab in Adult Chinese Subjects With Active Ankylosing Spondylitis |
|
- Biological: adalimumab
- Other: placebo
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of Participants Meeting the Assessment of Spondyloarthritis International Society (ASAS) ASAS20 Response Criteria
- Number of Participants Meeting the ASAS20 Response Criteria
- Number of Participants Meeting the ASAS40 Response Criteria
- (and 9 more...)
|
344 |
All |
18 Years to 65 Years (Adult) |
NCT01114880 |
M11-991 |
|
January 2010 |
September 2010 |
February 2011 |
May 3, 2010 |
December 1, 2011 |
November 4, 2011 |
- Site Reference ID/Investigator# 24054
Hefei, Anhui, China - Site Reference ID/Investigator# 25522
Beijing, China - Site Reference ID/Investigator# 24055
Beijing, China - (and 6 more...)
|
| 42 |
NCT02557308 |
Recruiting |
An Observational Study to Evaluate Safety and Efficacy of Remsima™ in Patients With Ankylosing Spondylitis |
|
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Detection of events of special interest in AS patients
- Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
- Bath Ankylosing Spondylitis Functional Index (BASFI)
- Visual Analogue Scale (VAS) or Numerical Rating Scale (NRS) Physician and Patient Global Assessment of Disease Status
|
1000 |
All |
18 Years and older (Adult, Senior) |
NCT02557308 |
CT-P13 4.4 |
|
August 2014 |
December 2019 |
June 2026 |
September 23, 2015 |
June 14, 2017 |
|
- TaeHwan Kim
Seoul, Korea, Republic of
|
| 43 |
NCT02389075 |
Recruiting |
The Colonic Microbiome and Mucosal Immunity in Inflammatory Bowel Disease and Ankylosing Spondylitis |
- Inflammatory Bowel Diseases (IBD)
- Ankylosing Spondylitis (AS)
|
- Procedure: Pinch biopsies
- Procedure: Flexible sigmoidoscopy
|
Observational |
|
- University of Colorado, Denver
|
Other |
- Observational Model: Case-Control
- Time Perspective: Cross-Sectional
|
- IEL characteristics in IBD, AS, and healthy controls
- Microbiome Differences in IBD, AS, and healthy controls
- Microbiome changes are reflected in IELs
|
60 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT02389075 |
14-1507
UL1TR001082 |
|
March 2015 |
June 2018 |
June 2018 |
March 17, 2015 |
February 12, 2018 |
|
- Denver, Colorado, United States
|
| 44 |
NCT02750592 |
Active, not recruiting |
Study of Efficacy and Safety of Secukinumab in Japanese Patients With Active Ankylosing Spondylitis |
|
|
Interventional |
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Assessment of SpondyloArthritis International Society criteria (ASAS) 20 response
- ASAS 40 response
- Bath Ankylosing Spondylitis Disease Activity (BASDAI) 50
- (and 9 more...)
|
29 |
All |
18 Years and older (Adult, Senior) |
NCT02750592 |
CAIN457H1301 |
|
March 22, 2016 |
July 3, 2017 |
May 8, 2018 |
April 25, 2016 |
April 21, 2017 |
|
- Novartis Investigative Site
Kitakyushu-city, Fukuoka, Japan - Novartis Investigative Site
Kita-gun, Kagawa, Japan - Novartis Investigative Site
Nankoku-city, Kochi, Japan - (and 7 more...)
|
| 45 |
NCT02763111 |
Completed |
Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of Various Doses of BCD-085 in Patients With Active Ankylosing Spondylitis |
|
- Drug: BCD-085
- Other: Placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Ratio of patients with ASAS20 response after 16 weeks of therapy
- Ratio of patients with ASAS20 response after 4, 8, 12 weeks of therapy
- Ratio of patients with ASAS40 response after 4, 8, 12, 16 weeks of therapy
- (and 24 more...)
|
88 |
All |
18 Years to 65 Years (Adult) |
NCT02763111 |
BCD-085-3 |
|
September 2016 |
June 2017 |
June 2017 |
May 5, 2016 |
February 21, 2018 |
|
|
| 46 |
NCT01850121 |
Completed |
Remicade in the Treatment of Patients With Active Ankylosing Spondylitis |
|
|
Observational |
|
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Bath AS disease activity score (BASDAI)
|
19 |
All |
18 Years to 60 Years (Adult) |
NCT01850121 |
2002-11-04 amended 2002-01-08 |
|
January 2003 |
May 2008 |
May 2008 |
May 9, 2013 |
August 9, 2016 |
|
- Sahlgrenska University Hospital
Gothenburg, Sweden
|
| 47 |
NCT01061723 |
Completed
Has Results |
Dose Ranging Study to Evaluate the Efficacy and Safety of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis |
|
- Drug: Sarilumab
- Drug: Placebo
|
Interventional |
Phase 2 |
- Sanofi
- Regeneron Pharmaceuticals
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percentage of Participants Who Achieved 20% Response According to the Assessment in Ankylosing Spondylitis (AS) Working Group Criteria for Response (ASAS20) at Week 12
- Percentage of Participants Who Achieved 40% Response According to the Assessment in AS Working Group Criteria for Response (ASAS40) at Week 12
- Percentage of Participants Who Achieved Partial Remission According to the Assessment in AS Working Group Criteria for Response (ASAS) at Week 12
- (and 9 more...)
|
301 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT01061723 |
DRI11073
2009-016068-35 |
ALIGN |
February 2010 |
June 2011 |
June 2011 |
February 3, 2010 |
August 8, 2017 |
August 8, 2017 |
- Investigational Site Number 840006
Birmingham, Alabama, United States - Investigational Site Number 840033
Anaheim, California, United States - Investigational Site Number 840027
Los Angeles, California, United States - (and 77 more...)
|
| 48 |
NCT01421303 |
Completed
Has Results |
Work Productivity in Active Ankylosing Spondylitis (AS) Patients Treated With Enbrel. |
|
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Work Productivity and Activity Impairment Questionnaire - Ankylosing Spondylitis (WPAI-AS) Scale Scores at Baseline
- Work Productivity and Activity Impairment Questionnaire - Ankylosing Spondylitis (WPAI-AS) Scale Scores at Month 6
- Work Productivity and Activity Impairment Questionnaire - Ankylosing Spondylitis (WPAI-AS) Scale Scores at Month 12
- (and 19 more...)
|
80 |
All |
18 Years and older (Adult, Senior) |
NCT01421303 |
0881A3-4675
B1801053 |
AS@WORK |
October 2009 |
December 2013 |
December 2013 |
August 22, 2011 |
December 12, 2014 |
December 12, 2014 |
- Universitair Ziekenhuis Gent
Gent, Belgium
|
| 49 |
NCT02697968 |
Recruiting |
Electroacupuncture for Relieving Pain in Ankylosing Spondylitis |
|
- Device: Electroacupuncture
|
Interventional |
Not Applicable |
- The University of Hong Kong
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Pain Severity Numerical Rating Scale (NRS)
- Types and dosage of drug(s) intake
- Bath Ankylosing Spondylitis Functional Index (BASFI)
- (and 8 more...)
|
20 |
All |
Child, Adult, Senior |
NCT02697968 |
UW 15-458 |
|
March 2016 |
October 2017 |
June 2018 |
March 3, 2016 |
May 4, 2017 |
|
- The University of Hong Kong
Hong Kong, Hong Kong
|
| 50 |
NCT02809300 |
Recruiting |
Ankylosing Spondylitis and Antiphospholipid Antibodies |
- Ankylosing Spondylarthritis
|
- Biological: blood collection
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- presence or absence of APLA
|
80 |
All |
18 Years and older (Adult, Senior) |
NCT02809300 |
PA15075 |
ASAA |
November 2015 |
March 2017 |
|
June 22, 2016 |
June 23, 2016 |
|
- Chu Reims
France, Reims, France
|
Create an RSS feed from your search for:
Download the search results for: